Development of proprietary unique nM potent agonist of FPR/NOX2
for treatment of autoimmunity, inflammation and infections
ProNoxis focuses on the preclinical discovery of small-molecule drugs to treat chronic inflammation, autoimmunity and infections.
ProNoxis AB was founded in 2009 by LU Bioscience AB (LUBio), Karolinska Development AB, and Redoxis AB, as a Redoxis spin-off focusing on developing anti-inflammatory therapeutics targeting activation of the NADPH oxidase complex (NOX2).
Since 2024, Pronoxis AB is owned by its founder and CEO Dr. Peter Olofsson-Sahl